Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Kappos L, et al. Among authors: meluzinova e. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Lancet. 2008. PMID: 18970976 Clinical Trial.
Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia.
Jerie M, Vackova Z, Vojtech Z, Mares J, Meluzinova E, Krajciova J, Vymazal J, Cerna H, Martinek J. Jerie M, et al. Among authors: meluzinova e. Transl Neurosci. 2022 Oct 10;13(1):361-368. doi: 10.1515/tnsci-2022-0249. eCollection 2022 Jan 1. Transl Neurosci. 2022. PMID: 36304096 Free PMC article.
IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
Petržalka M, Meluzínová E, Libertínová J, Mojžišová H, Hanzalová J, Ročková P, Elišák M, Kmetonyová S, Šanda J, Sobek O, Marusič P. Petržalka M, et al. Among authors: meluzinova e. PLoS One. 2022 Jun 27;17(6):e0270607. doi: 10.1371/journal.pone.0270607. eCollection 2022. PLoS One. 2022. PMID: 35759479 Free PMC article.
Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry.
Vališ M, Pavelek Z, Novotný M, Klímová B, Šarláková J, Halúsková S, Peterka M, Štětkárová I, Štourač P, Mareš J, Hradílek P, Ampapa R, Vachová M, Recmanová E, Meluzínová E. Vališ M, et al. Among authors: meluzinova e. Front Neurol. 2022 Apr 18;13:851426. doi: 10.3389/fneur.2022.851426. eCollection 2022. Front Neurol. 2022. PMID: 35518208 Free PMC article.
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic.
Hradilek P, Meluzinova E, Zapletalova O, Hanulikova P, Horakova D, Woznicova I, Pavliska L, Stetkarova I, Valis M, Stourac P, Adamkova J, Ampapa R, Vachova M, Mares J. Hradilek P, et al. Among authors: meluzinova e. Mult Scler Relat Disord. 2022 Mar;59:103391. doi: 10.1016/j.msard.2021.103391. Epub 2021 Nov 28. Mult Scler Relat Disord. 2022. PMID: 35240415
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.
35 results